Species and strain differences in target organ alkylation and toxicity by 4-ipomeanol: Predictive value of covalent binding in studies of target organ toxicities by reactive metabolites

doi:10.1016/0006-2952(79)90074-1

Biochemical Pharmacology

Volume 28, Issue 23, 1 December 1979, Pages 3367-3372

https://doi.org/10.1016/0006-2952(79)90074-1 Get rights and content

Abstract

The organ specificities of the in vivo covalent binding of 4-ipomeanol were closely correlated with the patterns of organ-specific damage by 4-ipomeanol in several different animal species and strains. In all species tested, the lung was a major target for 4-ipomeanol covalent binding and toxicity. In the hamster and the mouse, 4-ipomeanol caused liver necrosis and kidney necrosis, respectively, in addition to pulmonary damage. Correspondingly, high levels of covalent binding of 4-ipomeanol occurred in these target organs in these species. These in vivo results, in addition to studies of the in vitro covalent binding of 4-ipomeanol in microsome preparations from the various target tissues, were consistent with the view that the organ-specific toxicities of 4-ipomeanol were caused by a highly reactive 4-ipomeanol metabolite(s) primarily produced in situ in the respective target tissues. The present results suggest that studies of both the in vivo and the in vitro covalent binding of 4-ipomeanol may have some utility in predicting the target organ specificity of 4-ipomeanol toxicity in other species. The present investigations also have identified some relevant new in vivo toxicity models for future studies of the relationships between the metabolism and the toxicity of 4-ipomeanol.

References (18)

M.R. Boyd et al.
Biochim. biophys. Acta
(1974)
M.R. Boyd et al.
Toxic. appl. Pharmac.
(1975)
T. Omura et al.
J. biol. Chem.
(1964)
C.A. Williams et al.
J. biol. Chem.
(1962)
C.R. Wolf et al.
Chem. Biol. Interacts
(1978)
H.A. Sasame et al.
Biochem. biophys. Res. Commun.
(1978)
M.R. Boyd et al.
J. Pharmac. exp. Ther.
(1978)
M.R. Boyd et al.
J. Pharmac. exp. Ther.
(1978)
M.R. Boyd
Nature, Lond.
(1977)

There are more references available in the full text version of this article.

Cited by (69)

Selected Pneumotoxic Agents
2018, Comprehensive Toxicology: Third Edition
The toxicity of environmental chemicals, that is, nontherapeutic agents, to respiratory tissues is described in significant detail throughout this volume. In the vast majority of cases, these environmental toxicants are inhaled chemicals that interact with respiratory cells on a contact basis, after inhalation. There is, however, an ever-expanding repertoire of chemicals that produce selective or specific toxicity to cells within the respiratory system after systemic circulation throughout the biological system. Many of these chemicals are therapeutic agents such as bleomycin (BLM) or amiodarone (AM), and some are nontherapeutic chemicals such as 3-methylindole (3MI), aflatoxin B₁ (AFB₁), butylated hydroxytoluene (BHT), halogenated hydrocarbons, naphthalenes, paraquat (1,19-dimethyl-4,49-bipyridilium, PQ), the pyrrolizidine alkaloids (PZAs), and the substituted furans that are ingested and circulated systemically. This article deals with chemicals that are known to cause damage to respiratory tissues following exposure and the mechanisms of their toxicity, which is generally mediated by oxidative metabolism of the chemicals to reactive electrophiles by cytochrome P450 enzymes in cells of the respiratory tract. These compounds are generally toxic to nonciliated bronchiolar epithelial cells and alveolar epithelial cells of the gas exchange region although some agents are highly toxic to nasal epithelial or pulmonary endothelial cells. The purpose of this chapter is to provide chemical and biochemical insights into the generalized mechanisms of toxicity of certain circulating pneumotoxicants, through the enumeration and compilation of a few examples of well-documented, chemically induced lung damage.
Metabolic Activation and Toxicities of Furanoterpenoids
2016, Advances in Molecular Toxicology
Citation Excerpt :
In 2013, Oliver and coworkers developed the first Cyp4b1-null mouse model and confirmed that the bioactivation of 4-IPO by murine P450 4B1 in mice leads to pulmonary toxicity [86]. Nonetheless, because of the interspecies differences between human and other mammalian homologs, the native human P450 4B1, an enzyme which has a serine residue at position 427 in the meander region near the heme-binding site, is unable to metabolize 4-IPO [73,80,87–90]. Wiek and coworkers reported that the native human P450 4B1 did not cause cytotoxicity, even at the highest concentration of 4-IPO applied (290 μM) [91].
This chapter introduces the bioactivation and toxicity of furanoterpenoids, particularly their hepatotoxicity. It starts with a brief description of biosynthesis of furanoterpenoids, followed by mechanisms of metabolic activation of furan-containing compounds and the interactions of reactive metabolites of furanoids with proteins. A total of five furanoterpenoids, i.e., 4-ipomeanol, teucrin A, diosbulbin B, 8-epidiosbulbin E acetate, and toosendanin, are discussed as examples. The chapter covers (1) the natural source and toxicities of the furanoterpenoids; (2) identification of reactive metabolites and major cytochromes P450 involved in the metabolic activation of the furan-containing compounds; and (3) protein modifications induced by the reactive metabolites of the furanoids. It also describes a newly developed approach to screen potentially harmful furan-containing compounds from complicated mixtures.
Development of Antioxidant and Xenobiotic Metabolizing Enzyme Systems
2014, The Lung: Development, Aging and the Environment: Second Edition
The cellular composition and architectural organization of the adult distal respiratory system (trachea, bronchi, and lungs) is highly complex. The respiratory system is composed of a large number of morphologically distinct cell phenotypes organized into a highly-branched series of tissues surrounding air passages. This very complex structure begins as an evagination of the undifferentiated epithelium from the foregut into a surrounding mesenchymal bundle. All of the developmental stages (embryonic, pseudoglandular, canalicular, and saccular) associated with the transformation from this simple tubular structure into a highly complex organ system are potentially susceptible to modification by toxic agents. These stages have been reviewed in more detail in earlier chapters. The susceptibility of the lung as a target organ for specific toxicants may be altered by the cellular processes involved in each of these stages of development.
Selected Pneumotoxic Agents
2010, Comprehensive Toxicology, Second Edition
The toxicity of environmental chemicals, that is, nontherapeutic agents, to respiratory tissues is described in significant detail throughout this volume. In the vast majority of cases, these environmental toxicants are inhaled chemicals that interact with respiratory cells on a contact basis, after inhalation. There is, however, an ever-expanding repertoire of chemicals that produce selective or specific toxicity to cells within the respiratory system after systemic circulation throughout the biological system. Many of these chemicals are therapeutic agents such as bleomycin (BLM) or amiodarone (AM) and some are nontherapeutic chemicals such as 3-methylindole (3MI), aflatoxin B1 (AFB1), butylated hydroxytoluene (BHT), halogenated hydrocarbons, naphthalenes, paraquat (1,19-dimethyl-4, 49-bipyridilium, PQ), the pyrrolizidine alkaloids (PZAs), and the substituted furans that are ingested and circulated systemically. This chapter deals with chemicals that are known to cause damage to respiratory tissues following exposure and the mechanisms of their toxicity, which is generally mediated by oxidative metabolism of the chemicals to reactive electrophiles by cytochrome P450 enzymes in cells of the respiratory tract. These compounds are generally toxic to nonciliated bronchiolar epithelial cells and alveolar epithelial cells of the gas exchange region, although some agents are highly toxic to nasal epithelial or pulmonary endothelial cells. The purpose of this chapter is to provide chemical and biochemical insights into the generalized mechanisms of toxicity of certain circulating pneumotoxicants, through the enumeration and compilation of a few examples of well-documented, chemically induced lung damage.
Pulmonary Developmental Responses to Toxicants
2010, Comprehensive Toxicology, Second Edition
Childhood lung disease is reaching epidemic proportions in the United States, especially in polluted urban environments. Epidemiologic studies suggest that early exposure to environmental pollutants is associated with childhood airway disease which persists into adulthood; however, the impact of lung-targeted toxicants on the respiratory system of pre- and postnatal animals is not well defined. The pattern of lung development itself may play a significant role in modulating the toxic response with significant portions of lung morphogenesis and cytodifferentiation occurring during the postnatal period. The enzyme systems responsible for bioactivation and detoxification differentiate during the perinatal period, with the majority of differentiation activity occurring for an extended period of time after birth. In addition, each enzyme system has a different pattern of differentiation during pre- and postnatal lung development. The risk of injury to a developing lung from an environmental contaminant known to target the lung in adults must be evaluated with two considerations: (1) The toxicant may have its impact by altering the processes of morphogenesis and cytodifferentiation, resulting in differential expression or organization of the lung in the adult. (2) Factors such as the stage of morphogenesis and differentiation of various subcompartments of the lungs during the time of exposure may significantly increase the severity of the toxic response. An effort must be made to separate the effects on the respiratory system produced by maternal exposure, either prior to parturition or during the suckling phase of postnatal growth, from the impacts of direct exposure on the postnatal animal. Alteration of the differentiated expression of a particular enzyme system or other functional protein by exposure during lung development, which does not lead to direct changes in lung function, may not produce adverse responses by a particular toxicant in the respiratory system.
Development of Antioxidant and Xenobiotic Metabolizing Enzyme Systems
2003, The Lung: Development, Aging and The Environment
This chapter describes the pattern of differentiation for antioxidant enzyme pathways as well as bioactivation detoxification enzyme systems during pre- and postnatal lung development. During both the pre- and postnatal period of lung development, there are rapid rates of cellular differentiation, cell division, and alveolarization occurring, making the early postnatal lung uniquely susceptible to injury by environmental oxidant and toxic air pollutants. The enzyme systems responsible for protection from oxidant injury and toxicant-induced injury differentiate during the perinatal period, with the majority of differentiation activity occurring for an extended period of time after birth. Each of these enzyme systems is expressed in a different pattern during pre- and postnatal lung development. Antioxidants and antioxidant enzymes protect the lung from oxidant pollutants such as ozone and nitrogen dioxide. Xenobiotic metabolizing enzymes act on compounds to make them more water-soluble and increase their rate of elimination. In general, the pulmonary antioxidant enzyme system develops during the last 10–15% of gestation in humans as well as in laboratory animals such as rats, hamsters, guinea pigs, rabbits, and lambs. CYP monooxygenases are expressed later during lung development, suggesting a role in protecting the lung from exogenous, rather than endogenous, compounds.

View all citing articles on Scopus

^☆: Portions of this work were presented at the Annual Meeting of the Society of Toxicology, March 12–16, 1978, San Francisco, CA [Abstr.: Toxic, appl. Pharmac.45, 267 (1978)].

^☆☆: Requests for reprints should be directed to: Dr. Michael Boyd, Bldg. 10, Rm. 6N-105. National Institutes of Health, Bethesda, MD 20205, U.S.A.

View full text

Species and strain differences in target organ alkylation and toxicity by 4-ipomeanol: Predictive value of covalent binding in studies of target organ toxicities by reactive metabolites☆,☆☆

Abstract

Biochim. biophys. Acta

Toxic. appl. Pharmac.

J. biol. Chem.

J. biol. Chem.

Chem. Biol. Interacts

Biochem. biophys. Res. Commun.

J. Pharmac. exp. Ther.

J. Pharmac. exp. Ther.

Nature, Lond.